Nasal calcitonin formulation

Details Nasal calcitonin formulation Nasal calcitonin formulation

2004-02-05

2009-06-30

Haghighatian, Mina (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S045000, C424S455000, C514S002600, C514S003100, C514S012200

Reissue Patent

active

RE040812

ABSTRACT:
delete-start id="DEL-S-00001" date="20090630" ?A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.delete-end id="DEL-S-00001" ?insert-start id="INS-S-00001" date="20090630" ?A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof.insert-end id="INS-S-00001" ?

REFERENCES:
patent: 4151276 (1979-04-01), Caulin et al.
patent: 4690952 (1987-09-01), Kagatani et al.
patent: 4788221 (1988-11-01), Kagatani et al.
patent: 4845080 (1989-07-01), Fischer
patent: 4900730 (1990-02-01), Miyauchi
patent: 5023252 (1991-06-01), Hseih
patent: 5026825 (1991-06-01), Grebow et al.
patent: 5059587 (1991-10-01), Yamamoto et al.
patent: 5124315 (1992-06-01), Ceschel et al.
patent: 5183802 (1993-02-01), Aliverti et al.
patent: 5234906 (1993-08-01), Young et al.
patent: 5279836 (1994-01-01), Nicolaus
patent: 5281580 (1994-01-01), Yamamoto et al.
patent: 5310727 (1994-05-01), Lattanzi et al.
patent: 5496801 (1996-03-01), Holthuis et al.
patent: 5514365 (1996-05-01), Mardente et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5536508 (1996-07-01), Canal et al.
patent: 5571788 (1996-11-01), Arvinte et al.
patent: 5593962 (1997-01-01), Arvinte et al.
patent: 5637309 (1997-06-01), Tajima et al.
patent: 5654000 (1997-08-01), Poli et al.
patent: 5665700 (1997-09-01), Cho et al.
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5700486 (1997-12-01), Canal et al.
patent: 5714477 (1998-02-01), Einarsson
patent: 5719122 (1998-02-01), Chiodini et al.
patent: 5725871 (1998-03-01), Illum
patent: 5726154 (1998-03-01), Baudys et al.
patent: 5733569 (1998-03-01), Azria et al.
patent: 5733572 (1998-03-01), Unger et al.
patent: 5759565 (1998-06-01), Azria et al.
patent: 5759566 (1998-06-01), Poli et al.
patent: 5776886 (1998-07-01), Inamoto et al.
patent: 5858391 (1999-01-01), Cuca et al.
patent: 5912014 (1999-06-01), Stern et al.
patent: 5938654 (1999-08-01), Wong et al.
patent: 5968899 (1999-10-01), Sekine et al.
patent: 6008189 (1999-12-01), Inamoto et al.
patent: 6017538 (2000-01-01), Druilhe et al.
patent: 6086918 (2000-07-01), Stern et al.
patent: 6087338 (2000-07-01), Veronesi et al.
patent: 6107277 (2000-08-01), Veronesi et al.
patent: 6149893 (2000-11-01), Mardente et al.
patent: 6153582 (2000-11-01), Skelnik
patent: 6348207 (2002-02-01), Milstein et al.
patent: 6440392 (2002-08-01), Stern
patent: 6440446 (2002-08-01), Yoshizane et al.
patent: 6447785 (2002-09-01), Donovan
patent: 6509006 (2003-01-01), Platz et al.
patent: 0 115 627 (1984-08-01), None
patent: 0 327 756 (1989-08-01), None
patent: 0 358 234 (1990-03-01), None
patent: 0 371 010 (1990-05-01), None
patent: 0 418 697 (1991-03-01), None
patent: 0 489 217 (1992-06-01), None
patent: 0 726 075 (1996-08-01), None
patent: 0 809 512 (1997-12-01), None
patent: 2092002 (1982-08-01), None
patent: 05 078258 (1993-03-01), None
Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims,Unigene Laboratories Inc., et al.v.Apotex Inc., et al.,Civil Action No. 06-CV-5571—RPP-THK, EFC Case (S.D.N.Y.) Sep. 20, 2006.
Dua et al., International Journal of Pharmaceutics 147, 1997, pp. 233-242 “The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits.”
P. Graf et al., Clin., Exp. Allergy, vol. 25:395-400; 1995 “Benzalkoium chloride in a decongestant nasal spray aggravatesRhinitis medicamentosain healthy volunteers”.
H. Hallen et al., Clin. Exp. Allergy, vol. 25:401-405; 1995 “Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers”.
Berg et al., Laryngoscope 104:1153-1158; 1994 “The Effect of Decongestive Nosedrops on Human Respiratory Mucosa In Vitro”.
P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992 “The effects of calcitonin nsala preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test”.
Remington, The Science and Practice of Pharmacy, 20thEdition, Philadelphia (USA) Jan. 2000, Chapter 47, pp. 922-923.
Repertorio Farmaceutico Italiano, REFI 4a Edizione (REFI 4thEdition), 1990, p. A 212, (Calcitonina Spray Nasale Arnmour, and p. A223 “Carbicalcin Spray”, Farmindustria, Associazione dell'Idustria Farmaceutica (National Association of the Pharmaceutical Industry)—CEDOF Editor, 1990.
The Merck Index, 13thEdition, 2001, p. 3576.
Physicians' Desk Reference-PDR 53 Edition 1999, pp. 2057-2059.
Romeijn S.G., et al., Int. J. Pharm.,1996,135/1-2 (137-145), “The Effect of Nasal Drug Formulations on Ciliary Beating in vitro”, abstract.
Schipper N.G.M., et al., Calcif. Tissue Int.,1995, 56/4 (280-282) “Methylated (beta)-cyclodextrins are Able to Improve the Nasal Absorption of Salmon Calcitonin”, abstract.
Marttin E., Pharm. Res., May 1997, 14 (5): 631-7, “Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers”, abstract.
Abe K., et al., Chem. Pharm. Bull (Tokyo) Dec. 1995; 43 (12): 2232-7, “Enhanced Nasal Delivery of Luteinizing Hormone Releasing Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-beta-cyclodextrin”, abstract.
Kagatani S., et al., Pharm. Res. 1996 13/5 (739-743), “Enhancement of Nasal Salmon Calcitonin Absorption by Lauroyclarnitine Chloride in Rats”, abstract.
Morimoto K., et al., J. Pharma. Pharmacol. 1985 37/2 (134-136) “Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel”, abstract.
Martin E., et al., Pharm Res May 1997; 14(5) : 631-7, “Confocal laser scanning microscopic visualization of the transport of Dextrans after Nasal Administration to Rats: Effects of Absorption Enhancers”, abstract.
Kurosaki Y., et al., J. Pharmacobiodyn Dec. 1988; 11 (12) : 824-32, “Application of Propranolol to the Keratinized Oral Mucosa: Avoidance of First-Pass Elimination and the Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form”, abstract.
Okamoto H., et al., J. Pharm. Pharmacol Jul. 1987; 39 (7) : 531-4, “Enhanced penetration of mitromycin C through hairless mouse and rats skin by enhancers with terpene moieties”, abstract.
Sugibayashi K., et al., J. Pharm. Pharmacol Aug. 1985; 37 (8) : 578-80, “Effect of the Absorption Enhancer, Azone, on the Transport of 5-Fluorouracil Across Hairless Rat Skin”, abstract.
Vermehren C:, et al., Drug Metab Dispos Sep. 1997; 25 (9): 1083-8, “Absorption and Metabolism of the Absorption Enhancer Didecanoylphosphatidylcholine in Rabbit Nasal Epithelium in vivo”, abstract.
Jacobs M.A., et al., Diabetes Nov. 1993; 41 (11) : 1649-55, “The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers”, abstract.
Schipper N.G., et al., Pharm Res Nov. 1996; 13 (11) : 1686-92, “Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells”, abstract.
Pillion D.J., et al., J. Pharm. Sci. Nov. 1995; 84 (11) : 1276-9, “DS-1, A Modified Quillaja Saponin, Enhances Ocula and Nasal Absorption of Insulin”, abstract.
Agerholm C., et al., J. Pharm. Sci. Dec. 1994; 83 (12) : 1706-11, “Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in Rabbits”, abstract.
Critchley H., et al.,

Affiliated with

Also associated with

Rating

Nasal calcitonin formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nasal calcitonin formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nasal calcitonin formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077988